Corcept Therapeutics

www.corcept.com

Time filter

Source Type

Patent
Corcept Therapeutics | Date: 2016-08-12

This invention provides for an improved method for differentially diagnosing ACTH-dependent Cushings syndrome. Current practice for differentially diagnosing ectopic ACTH syndrome and Cushings Disease measures relative ACTH concentrations from the inferior petrosal venous sinus compared to fluid obtained from a periphery venous sample. This is performed before and after administration of exogenous corticotropin releasing factor, or after administration of metyrapone. This invention uses glucocorticoid receptor antagonists to induce release of endogenous CRH which stimulates ACTH to increase in patients with ectopic ACTH syndrome but not in those with Cushings Disease.


Devices, systems, and methods for use in managing treatment of a chronic disorder with pharmaceutical or therapeutic compounds by tracking symptoms associated with the disorder. Methods include inputting patient attributes, factors and various and other data relating to the patient in conjunction with one or more symptoms into a symptom tracking system and outputting a report of the data tracked over time to any of the patient, a medical professional and a drug developer to improve identification of a relapse of the chronic condition and improve management of the treatment regimen for any and all patients.


Devices, systems, and methods for use in managing patient treatments utilizing pharmaceutical or therapeutic compounds. Methods include accessing one or more fields of information relating to any of a patient, physician and drug treatment and relating the one or more fields, or combination thereof, to a particular attribute or outcome. By analyzing the one or more fields of data in relation to the attribute or outcome, the system determines suitability of an intervention(s) and tasks the intervention(s) to one or more entities to facilitate the desired attribute or outcome. In certain aspects, the system facilitates identification of complex relationships and trends between seemingly unrelated fields of information and outputs information for use in an intervention or various other purposes according to the attribute or outcome desired by the user.


The present invention provides treatment of fatty liver disease using a class of pyrimidinedione cyclohexyl compounds.


Patent
Corcept Therapeutics | Date: 2014-11-07

The present invention provides a class of pyrimidinedione cyclohexyl compounds and methods of using these compounds as glucocorticoid receptor modulators.


Devices, systems, and methods for use in managing treatment of a chronic disorder with pharmaceutical or therapeutic compounds by tracking symptoms associated with the disorder. Methods include inputting patient attributes, factors and various and other data relating to the patient in conjunction with one or more symptoms into a symptom tracking system and outputting a report of the data tracked over time to any of the patient, a medical professional and a drug developer to improve identification of a relapse of the chronic condition and improve management of the treatment regimen for any and all patients.


Patent
Corcept Therapeutics | Date: 2016-02-02

The present invention provides heteroaryl ketone fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.


Patent
Corcept Therapeutics | Date: 2016-04-20

The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushings syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.


Patent
Corcept Therapeutics | Date: 2014-09-16

The present invention provides heteroaryl ketone fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.


Patent
Corcept Therapeutics | Date: 2014-11-21

The present invention provides octahydro fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.

Loading Corcept Therapeutics collaborators
Loading Corcept Therapeutics collaborators